Filed: November 20, 2015
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`————————————————
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`————————————————
`
`MYLAN PHARMACEUTICALS INC.
`
`Petitioner,
`
`v.
`
`YEDA RESEARCH & DEVELOPMENT CO. LTD.
`
`Patent Owner.
`
`————————————————
`
`Case IPR2015-00644
`
`Patent No. 8,399,413
`
`————————————————
`
`UPDATED LIST OF PATENT OWNER’S EXHIBITS
`
`
`
`
`
`
`
`

`
`
`
`Pursuant to 37 C.F.R. § 42.63(e), Patent Owner submits the following
`
`current exhibit list.
`
`Exhibit No.
`
`Description
`
`2001
`2002
`
`2003
`
`2004
`
`2005
`2006
`
`2007
`
`2008
`2009
`
`2010
`
`2011
`
`2012
`
`Teva Provides Update on Forte Trial (July 7, 2008)
`Franscisco J. Quintana et al., Systems Biology
`Approaches for the Study of Multiple Sclerosis, 12 J. Cellular &
`Molecular Med. 1087 (2008)
`David Virley, Developing Therapeutics for the
`Treatment of Multiple Sclerosis, 2 J. Am. Soc. Experimental
`Neurotherapeutics 638 (Oct. 2005)
`Manuel A. Friese et al., The Value of Animal Models For Drug
`Development in Multiple Sclerosis, 129 Brain 1940 (2006)
`Copaxone Prescribing Information (Jan. 2014)
`Dvora Teitelbaum et al., Suppression of Experimental
`Allergic Encephalomyelitis by a Synthetic Polypeptide, 1
`Eur. J. Immunology 242 (1971)
`Jill Conner, Glatiramer Acetate and Therapeutic Peptide
`Vaccines for Multiple Mclerosis,1 J. Autoimmun. &
`Cell Responses 3 (2014)
`Copaxone, Physicians Desk Reference 3231 (62 ed. 2008)
`Wiebke Schrempf and Tjalf Ziemssen, Glatiramer
`Acetate: Mechanisms of Action In Multiple Sclerosis, 6
`Autoimmun. Rev. 469 (2007)
`V.Wee Yong, Differential Mechanisms of Action of
`Interferon-β and Glatiramer Acetate in MS, 59
`Neurology 802 (2002)
`Suhayl Dhib-Jalbut, Mechanisms of Action of
`Interferons and Glatiramer Acetate in Multiple Sclerosis,
`58 Neurology S3–9 (Supp. 4 2002)
`O. Neuhaus et al., Pharmacokinetics and Pharmacodynamics of the
`Interferon-Betas, Glatiramer Acetate, and Mitoxantrone in Multiple
`Sclerosis, 259 (1-2) J. Neurol. Sci. 27-37 (2007)
`
`
`
`
`2
`
`

`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`
`2020
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`Oded Abramsky et al., Effect Of A Synthetic Polypeptide (COP 1)
`on Patients with Multiple Sclerosis and With Acute Disseminated
`Encephalomyelitis, 31 J. Neurol. Sci. 433 (1977)
`Murry B. Bornstein et al., Treatment of Multiple Sclerosis with a
`Synthetic Polypeptide: Preliminary Results, 105 Tran. Am. Neurol.
`Assoc. 348 (1980)
`Murry B. Bornstein et al., Multiple Sclerosis: Trial of a
`Synthetic Polypeptide, 11 Annals Neurol. 317 (1982)
`Murry B. Bornstein et al., A Pilot Trial of COP 1 in
`Exacerbating-Remitting Multiple Sclerosis, 13 New Engl. J.
`Med. 408 (1987)
`Sage Journals, Table of Contents,
`http://msj.sagepub.com/content/14/1_suppl.toc (Sept. 2008)
`Massimo Filippi et al., Effects of oral glatiramer
`acetate on clinical and MRI monitored disease activity in patients
`with relapsing multiple sclerosis: a multicentre, double-blind,
`randomised, placebo- controlled study,
`http://neurology.thelancet.com (Jan. 20, 2006)
`Yuval Ramot et al., Comparative Long-Term
`Preclinical Safety Evaluation of Two Glatiramoid
`Compounds (Glatiramer Acetate, Copaxone1, and TV-
`5010, Protiramer) in Rats and Monkeys, 40 Toxicol. Pathways 40
`(2012)
`U.S. Patent Application No. 2007/0161566 A1
`T. Ziemssen et al., Risk-benefit assessment of glatiramer acetate in
`multiple sclerosis, 24(13) Drug Safety 979 (2001)
`
`Teva News Release, Phase III Data Published in
`Annals of Neurology Show That a Higher
`Concentration Dose of Glatiramer Acetate Given Three
`Times a Week Reduced Annualized Relapse Rates in the Treatment
`of Relapsing-Remitting Multiple Sclerosis (July 1, 2013)
`Omar Khan et al., Three Times Weekly Glatiramer
`Acetate in Relapsing–Remitting Multiple Sclerosis, 73
`Annals Neurol. 705 (2013)
`Teva Press Release, Teva Reports First Quarter 2015
`Results (April 30, 2015)
`Kate McKeage, Glatiramer Acetate 40 mg/mL in
`Relapsing-Remitting Multiple Sclerosis: A Review, CNS
`Drugs (April 24, 2015)
`
`
`
`
`3
`
`

`
`2026
`
`2027
`2028
`
`2029
`
`2030
`
`2031
`
`2032
`
`2033
`
`2034
`
`K.P. Johnson et al., Copolymer 1 reduces relapse rate
`and improves disability in relapsing-remitting multiple sclerosis:
`Results of a phase I11 multicenter, double-blind, placebo-
`controlled trial, 45 Neurology 1268 (1995)
`
`Intentionally left Blank
`G. Comi, Forte: Results from a phase II, 1-year, Randomized,
`Double-blind, Parallel-Group, Dose Comparison Study with
`Glatiramer Acetate in Relapsing-remitting Multiple Sclerosis,
`Presented at World Congress on Treatment and Research in
`Multiple Sclerosis: 2008 Joint Meeting of the American, European,
`and Latin America Committees on Treatment and Research in
`Multiple Sclerosis, San Raffaele, Italy (ACTRIMS, ECTRIMS,
`LACTRIMS) (2008)
`Jerry S. Wolinsky et al., GLACIER: An open-label, randomized,
`multicenter study to assess the safety and tolerability of glatiramer
`acetate 40 mg three times weekly versus 20 mg daily in patients with
`relapsing-remitting multiple sclerosis, 4 Multiple Sclerosis and
`Related Disorders 370 (2015)
`C. Farina et al., Treatment of multiple sclerosis with Copaxone
`(COP): Elispot assay detects COP-induced interleukin-4 and
`interferon-gamma response in blood cells. 124 Brain 705 (2001).
`PRA, Multiple Sclerosis: Transform Your Clinical Trial with PRA
`(2012) (Peroutka Dep. Ex. 4)
`Opinion, Endo Pharmaceuticals, Inc. v. Mylan Pharmaceuticals,
`Inc., No. 11-cv-00717, Document 226 (Jan. 28, 2014) (Peroutka
`Dep. Ex. 6)
`
`Donna Oksenberg et al., A single amino acid difference confers
`major pharmacological variation between human and rodent 5-HT-
`1B receptors, 360 Nature 161 (1992) (Peroutka Dep. Ex. 9)
`
`Shalit et al., Copolymer-1 (Copaxone®) induces in non-
`immunologic activation of connective tissue type mast cells, 97(1) J.
`Allergy And Clinical Immunology 345 (1996) (Peroutka Dep. Ex.
`12)
`
`
`
`
`4
`
`

`
`2035
`
`2036
`
`2037
`
`2038
`
`2039
`
`2040
`
`2041
`
`2042
`
`2043
`
`2044
`
`Order, Endo Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc.,
`No. 11-cv-00717, Document 310 (Apr. 8, 2014) (Peroutka Dep. Ex.
`15)
`
`M. Fridkis-Hareli et al., Binding motifs of copolymer 1 to multiple
`sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. .
`15;162(8):4697-704. (Apr. 1999)
`Notice of Abandonment APN 11/651,212 (03-09-10)
`
`B. Meibohm & H. Derendorf, Basic concepts of
`pharmacokinetic/pharmacodynamic (PK/PD) modelling.35(10) ,
`401-413 (1997)
`
`P.H. Lambert & P.E. Laurent, Intradermal vaccine delivery: will
`new delivery systems transform vaccine administration? 26(26)
`Vaccine, 3197-208 (2008)
`
`G. Glenn et al., Transcutaneous immunization and
`immunostimulant strategies, 23(4) Immunology And Allergy
`Clinics Of N. Am., 787-813 (2003)
`
`C.D. Partidos et al., Immunity under the skin: potential application
`for topical delivery of vaccines, 21Vaccine 776 (2003)
`
`C. Ghose et al., Transcutaneous immunization with Clostridium
`difficile toxoid A induces systemic and mucosal immune responses
`and toxin A-neutralizing antibodies in mice, 75 Infection &
`Immunity 2326 (2007)
`
`G. Glenn et al., Transcutaneous immunization with cholera toxin
`protects mice against lethal mucosal toxin challenge, 161(7) J.
`Immunology 3211 (1998)
`
`R. Aharoni et al., Specific Th2 cells accumulate in the central
`nervous system of mice protected against experimental autoimmune
`encephalomyelitis by copolymer 1, 97 Proc. Nat’l Acad. Sci. U.S.A.,
`11472 (2000)
`
`
`
`
`5
`
`

`
`2045
`
`2046
`
`2047
`
`2048
`
`2049
`
`2050
`
`2051
`
`2052
`
`2053
`
`2054
`
`2055
`
`2056
`
`R. Arnon & R. Aharoni, Mechanism of action of glatiramer acetate
`in multiple sclerosis and its potential for the development of new
`applications 101 Proc. Nat’l Acad. Sci U.S.A., 14593 (Supp. 2
`2004)
`
`H. Varkony et al., The Glatiramoid Class of Immunomodulator
`Drugs, 10 Expert Opinion Pharmacotherapy 656 (2009)
`
`G. Comi & L. Moiola, Glatiramer acetate, 17 Neurologia 244
`(2002)
`
`Chabot et al., Cytokine production in T lymphocyte-microglia
`interaction is attenuated by glatiramer acetate: a mechanism for
`therapeutic efficacy in multiple sclerosis, 8 Multiple Sclerosis 299
`(2002)
`
`T. Ziemssen, Neuroprotection and glatiramer acetate: the possible
`role in the treatment of multiple sclerosis, 541 Advanced
`Experimental Med. Biology 111 (2004)
`
`Schmeisser et al., Radioiodination of human interferon-alpha2
`interferes with binding of C-terminal specific antibodies. 238 J.
`Immunological Methods 81 (2000)
`
`Efimova et al., Changes in the secondary structure of proteins
`labeled with 125I: CD spectroscopy and enzymatic activity studies,
`264 J. Of Radioanalytical And Nuclear Chemistry, 91-96 (2005).
`Toutain P.L. and Bousquet-Mélou A., Plasma terminal half-life, 27
`J. Veterinary Pharmacological Therapy 427 (2004)
`
`G.B. Ryan & G. Majno, Acute inflammation. A review, 86(1) Am. J.
`Pathology 183 (1977)
`
`Shalit et al., Copolymer-1 (Copaxone®) induces in non-
`immunologic activation of connective tissue type mast cells, abstract
`650, J. Allergy & Clinical Immunology, 345 (1996)
`
`Imming et al., Drugs, their targets and the nature and number of
`drug targets, 5 Nature Revs. Drug Discov. 821 (2006) (Erratum in:
`6 Nature Revs. Drug Discov. 126 (2007))
`C.B. Pert et al., Properties of opiate-receptor binding in rat brain.
`70 Proc. Natl. Acad. Sci. U.S.A. 2243 (1973)
`
`
`
`
`6
`
`

`
`2057
`
`2058
`
`2059
`
`2060
`
`2061
`
`2062
`
`2063
`
`2064
`
`2065
`
`2066
`
`2067
`
`2068
`
`2069
`
`B. Petty et al., The effect of systemically administered recombinant
`human nerve growth factor in healthy human subjects. 36 Annals
`Neurol. 244 (1994)
`S.J. Peroutka, Antimigraine drug interactions with serotonin
`receptor subtypes in human brain. 23 Annals Neurol. 500 (1988)
`ALK Hestvik et al., Multiple sclerosis: glatiramer acetate induces
`anti-inflammatory T cells in the cerebrospinal fluid, 14 Multiple
`Sclerosis 749 (2008)
`R. Aharoni, The mechanism of action of glatiramer acetate in
`multiple sclerosis and beyond. 12 Autoimmun Rev. 543 (2013)
`D. Burger et al., Glatiramer acetate increases IL-1 receptor
`antagonist but decreases T cell-induced IL-1beta in human
`monocytes and multiple sclerosis. 106 Proc. Natl. Acad. Sci. U.S.A.
`4355 (2009)
`A. Mendes, M. Jose’ Sá, Classical immunomodulatory therapy in
`multiple sclerosis: how it acts, how it works, 69 Arq.
`Neuropsiquiatr. 536 (2011)
`R. Aharoni et al., Copolymer 1 induces T cells of the T helper type 2
`that crossreact with myelin basic protein and suppress experimental
`autoimmune encephalomyelitis. 94 Proc. Natl. Acad. Sci. U.S.A.
`10821 (1997)
`R. Aharoni et al., Bystander suppression of experimental
`autoimmune encephalomyelitis by T cell lines and clones of the Th2
`type induced by copolymer 1. 91 J. Neuroimmunol. 135 (1998)
`O. Neuhaus et al., Mechanisms of action of glatiramer acetate in
`multiple sclerosis. 56 Neurology 702 (2001)
`T. Ziemssen et al., Glatiramer acetate-specific T-helper 1- and 2-
`type cell lines produce BDNF: implications for multiple sclerosis
`therapy. Brain-derived neurotrophic factor, 125 Brain 2381 (2002)
`Miller et al., Treatment of multiple sclerosis with copolymer-1
`(Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-
`deviation. 92 J. Neuroimmunol. 113 (1998)
`Neuhaus et al., Multiple sclerosis: comparison of copolymer-1-
`reactive T cell lines from treated and untreated subjects reveals
`cytokine shift from T helper 1 to T helper 2 cells. 97 Proc. Natl.
`Acad. Sci. U.S.A. 7452 (2000)
`Duda et al., Glatiramer acetate (Copaxone) induces degenerate,
`Th2-polarized immune responses in patients with multiple sclerosis.
`105 J. Clin. Invest. 967 (2000)
`
`
`
`
`7
`
`

`
`2070
`
`2071
`
`2072
`
`2073
`
`2074
`
`2075
`
`2076
`
`2077
`
`2078
`
`2079
`
`2080
`
`2081
`
`2082
`
`2083
`
`Hori et al., Control of regulatory T cell development by the
`transcription factor Foxp3. 299 Science 1057 (2003)
`Brunkow et al., Disruption of a new forkhead/winged-helix protein,
`scurfin, results in the fatal lymphoproliferative disorder of the
`scurfy mouse, 27 Nature Genet. 68 (2001)
`Viglietta et al., DA. Loss of functional suppression by CD4+CD25+
`regulatory T cells in patients with multiple sclerosis. 199 J. Exp.
`Med. 971 (2005)
`Hong et al., Induction of CD4+CD25+ regulatory T cells by
`copolymer-I through activation of transcription factor Foxp3, 102
`Proc. Natl. Acad. Sci. U.S. A. 6449 (2005)
`Wekerle et al., Cellular immune reactivity within the CNS. Trends
`Neurosci. 9 TINS 271-277 (1986).
`W.F. Hickey, Migration of hematogenous cells through the blood-
`brain barrier and the initiation of CNS inflammation. 1 Brain
`Pathol. 97 (1999)
`Weber et al., Multiple sclerosis: glatiramer acetate inhibits
`monocyte reactivity in vitro and in vivo. 127 Brain 1370 (2004)
`Menge et al., Disease-modifying agents for multiple sclerosis:
`recent advances and future prospects, 68 Drugs 2445 (2008)
`Sodoyez et al., 125I-insulin: kinetics of interaction with its
`receptors and rate of degradation in vivo. 239 Am. J. Physiol. E3-8.
`(1980)
`Wroblewski VJ. Mechanism of deiodination of 125I-human growth
`hormone in vivo. Relevance to the study of protein disposition, 42
`Biochem. Pharmacol. 889 (1991)
`Alastair Monro, The paradoxical lack of interspecies correlation
`between plasma concentrations and chemical carcinogenicity, 18
`Regulatory Toxicology & Pharmacology 115 (1993)
`Robert T. O’Neill, Secondary endpoints cannot be validly analyzed
`if the primary endpoint does not demonstrate clear statistical
`significance, 18 Controlled Clinical Trials 550 (1997)
`Karsten Beer et al., The prevalence of injection-site reactions with
`disease-modifying therapies and their effect on adherence in
`patients with multiple sclerosis: an observational study, 11 BMC
`Neurology 144 (2011)
`Tjalf Ziemssen et al., Glatiramer acetate: mechanisms of action in
`multiple sclerosis, 79 Int’l Rev. Neurobiology 537 (2007)
`
`
`
`
`8
`
`

`
`2084
`
`2085
`
`2086
`
`2087
`
`2088
`
`2089
`
`2090
`
`2091
`
`2092
`
`2093
`
`2094
`
`2095
`
`Tjalf Ziemssen, Modulating processes within the central nervous
`system is central to therapeutic control of multiple sclerosis, 252 J.
`Neurology Suppl. 5 V/38-V.45 (2005)
`Tjalf Ziemssen et al., Presence of glatiramer acetate-specific TH2
`cells in the cerebrospinal fluid of patients with multiple sclerosis 12
`months after the start of therapy with glatiramer acetate. 1 J.
`Neurodegeneration & Regeneration 1 (Sept. 9, 2008)
`H.P. Rang et. al., Pharmacology, 106-119, Elsevier 2005 (5th ed.,
`1987)
`Donald W. Paty, The Interferon-β1b Clinical Trial and Its
`Implications for Other Trials, 36 Annals Neurology S113 (Supp.
`1994)
`Leonora K. Fisniku, Gray Matter Atrophy Is Related to Long-Term
`Disability in Multiple Sclerosis, 64 Annals Neurology 247 (2008)
`Omar Kahn et al., Three Times Weekly Glatiramer Acetate in
`Relapsing–Remitting Multiple Sclerosis, 73 Annals of Neurology
`705 (2013)
`Phillip D. Rumrill Jr., Multiple sclerosis: Medical and psychosocial
`aspects, etiology, incidence, and prevalence, 31 J. Vocational
`Rehabilitation 75 (2009)
`H.T. Katz et al., Successful desensitization to glatiramer acetate
`(Copaxone) in two patients with multiple sclerosis, 92 Abstract
`Book, 2003 Annual Meeting, American College of Allergy, Asthma
`& Immunology, New Orleans, LA (Jan. 2004)
`
`Maria Zellner et al., Quantitative validation of different protein
`precipitation methods in proteome analysis of blood platelets, 26
`Electrophoresis 2481 (2005)
`
`Mariana Castells, Rapid Desensitization for Hypersensitivity
`Reactions to Medications, 29 Immunology and Allergy Clinics of
`North America 585 (2009)
`Robert Zivadinov et al., MRI Indicators of Brain Tissue Loss: 3-
`Year Results of the Glatiramer Acetate Low-Frequency
`Administration (GALA) Open-Label Extension Study in Relapsing-
`Remitting Multiple Sclerosis, Presented at The American Academy
`of Neurology 2015 Annual Meeting, Washington, DC (Apr. 18-25,
`2015)
`E. Rubinchik et al., Responsiveness of human skin mast cells to
`repeated activation: an in vitro study, 53 Allergy 14 (1998)
`
`
`
`
`9
`
`

`
`2096
`
`2097
`2098
`2099
`2100
`2101
`
`2102
`
`2103
`
`2104
`2105
`2106
`2107
`2108
`
`2109
`2110
`
`2111
`
`2112
`
`2113
`
`2114
`
`2115
`2116
`
`2117
`
`Daniel Wynn et.al., Patient Experience with Glatiramer Acetate
`40mg/1 ml Three-Times Weekly Treatment for Relapsing-Remitting
`Multiple Sclerosis: Results from the Glacier Extension Study,
`Presented at The 8th Congress of the Pan-Asian Committee for
`Treatment and Research in Multiple Sclerosis, Seoul, Republic of
`Korea (Nov. 19-21, 2015).
`Avonex® (Inferno beta-1a) IM Injection (2008)
`Rebif Prescribing Information (2009)
`Extavia Highlights of Prescribing Information (2009)
`Curriculum Vitae of Edward J. Fox. MD., PhD., FAAN
`Soelberg Sorensen et al., Clinical Importance of neutralizing
`antibodies against interferon beta in patients with rerlapsing-
`remitting multiple sclerosis, 362 The Lancet 1184 (Oct. 11, 2003)
`Jan J.M. de Vijlder, Primary congenital hypothyroidism: defects in
`iodine pathway, 149 Eur. J. Endocrinology 247 (2003)
`Peptide and Protein Drug Delivery 203-246, Vincent H. L. Lee ed.,
`Marcel Dekker, Inc. 1991 (1990)
`Curriculum Vitae of Dr. Henry George Grabowski
`List of Testimony of Henry G. Grabowski
`Documents Relied Upon (Grabowski)
`Table: Approval Timeline, Multiple Sclerosis Drugs
`Figure: Copaxone® 40mg/mL Wholesale Dollar Sales (Q1 2014-
`Q3 2015)
`Figure: Copaxone® 40mg/mL Extended Units (Q1 2014- Q3 2015)
`Figure: Copaxone® 40mg/mL Total Prescriptions (Q1 2014- Q3
`2015)
`Figure: Copaxone® 40mg/mL New Prescriptions (Q1 2014- Q3
`2015)
`Figure: Multiple Sclerosis Drugs Share of Wholesale Dollar Sales
`(Q4 2009- Q3 2015)
`Figure: Multiple Sclerosis Drugs Share of Total Prescriptions (Q4
`2009- Q3 2015)
`Figure: Multiple Sclerosis Drugs Share of New Prescriptions (Q4
`2009- Q3 2015)
`Figure: Rationale for Requesting Copaxone
`Figure: Perception of 3-times-a-week Copaxone 40mg compared to
`Daily Copaxone 20mg
`Figure: Rationale for Discussing 20mg and 40mg for First Line
`Patients
`
`
`
`
`10
`
`

`
`2118
`
`2119
`2120
`2121
`
`2122
`
`2123
`
`2124
`
`2125
`
`2126
`
`2127
`
`2128
`
`2129
`2130
`2131
`2132
`2133
`2134
`
`Figure: Perceptions of Copaxone® 40mg compared to Daily
`Generic GA
`Figure: Perceptions of Copaxone® 40mg vs. 20mg
`Figure: Copaxone® Total Prescriptions (Q4 2009- Q3 2015)
`Figure: Copaxone® 20 mg/mL, Copaxone® 40 mg/mL, and
`Glatopa™ Net Prescriptions Flow (10/26/12-10/9/15)
`Table: Total Promotional Spending to Sales Ratio
`
`G. Comi et al., Early Treatment with glatiramer acetate is
`efficacious in delaying conversion to clinically definite multiple
`sclerosis in patients presenting with clinically isolated syndrome
`and brain lesions detected by MRI, 374 Lancet 1503 (Oct. 31, 2009)
`R.M. Valenzuela et al., Clinical response to glatiramer acetate
`correlates with modulation of IFN-γ and IL-4 expression in multiple
`sclerosis, 13 Multiple Sclerosis 754 (2007)
`Y. Blanco et al., Effect of glatiramer acetate (Copaxone®) on the
`immunophenotypic and cytokine profile and BDNF production in
`multiple sclerosis: A longitudinal study, 406 Neuroscience Letters
`270 (2006)
`M. Chen et al., Sustained immunological effects of Glatiramer
`acetate in patients with multiple sclerosis treated for over 6 years,
`201 J. of Neurological Sciences 71 (2002)
`Zhao Rong Chen et al., MU Receptor Binding of Some Commonly
`Used Opioids and Their Metabolites, 48 Life Sciences 2165 (1991)
`Alison Palkhivala, Doubling the Dose of Glatiramer Acetate Does
`Not Increase Efficacy, Medscape Medical News (Sept. 22, 2008)
`Declaration of Edward J. Fox, MD., PhD
`Curriculum Vitae of Robert William Gristwood PhD
`Curriculum Vitae of Tjalf Ziemssen
`Ziemssen’s MS clinical trials
`Declaration of Henry G. Grabowski, Ph.D.
`Declaration of Robert William Gristwood, Ph.D.
`
`
`
`11
`
`
`
`
`
`
`

`
`CERTIFICATION OF SERVICE
`
`The undersigned hereby certifies that the foregoing UPDATED LIST OF
`
`PATENT OWNER’S EXHIBITS was served electronically via e-mail on
`
`November 20, 2015 on the following:
`
`Jeffrey W. Guise
`
`jguise@wsgr.com
`
`Brandon M. White
`
`BMWhite@perkinscoie.com
`
`Shannon Bloodworth
`
`Sbloodworth@perkinscoie.com
`
`David Anstaett
`
`DAnstaett@perkinscoie.com
`
`Richard Torczon
`
`rtorczon@wsgr.com
`
`
`
`/Elizabeth Holland/
`Counsel for Patent Owner
`
`
`
`Dated:
`
`November 20, 2015
`
`12